Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modulating alloimmune responses with plasmapheresis and IVIG.

Daniel S Warren1, Christopher E Simpkins, Matthew Cooper

  • 1Departmernt of Surgery, Johns Hopkins University School of Medicine, Ross 765, 720 Rutland Ave., Baltimore, MD 21205, USA. dwarren1@jhmi.edu

Current Drug Targets. Cardiovascular & Haematological Disorders
|June 25, 2005
PubMed
Summary

Intravenous immunoglobulin (IVIG) therapies, alone or with plasmapheresis, enable kidney transplants by overcoming antibody barriers. These treatments improve outcomes for patients with anti-HLA or ABO incompatible kidneys.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fetal Echocardiography and Hyperoxia Testing after Serial Amnioinfusions: Results from the RAFT Trial Bilateral Renal Agenesis Arm.

Fetal diagnosis and therapy·2026
Same author

Clinical outcomes of histotripsy for liver malignancies: a systematic review of early clinical evidence.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same author

"There doesn't seem to be the help there for people who are carers": qualitative findings from a realist evaluation of hospital-to-home transitions.

Innovation in aging·2026
Same author

Neonatal Survival After Serial Amnioinfusions for Anhydramnios Due to Fetal Kidney Failure: The RAFT Clinical Trial.

JAMA·2026
Same author

Center-based obstacles and facilitators in the utilization of kidney paired donation in the United States, 2008-2023: A scoping review.

Transplantation reviews (Orlando, Fla.)·2026
Same author

Donor-Recipient Size Mismatch by Body Surface Area and Risk of Graft Failure in Kidney Transplantation.

Clinical transplantation·2026

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • Antibody-mediated barriers, including anti-HLA and anti-blood group antibodies, significantly hinder renal transplantation.
  • Increasing organ shortages lead to longer recipient waiting times for compatible kidneys.

Purpose of the Study:

  • To review desensitization therapies for incompatible renal transplantation.
  • To discuss the application of intravenous immunoglobulin (IVIG) and plasmapheresis in overcoming antibody barriers.

Main Methods:

  • Utilizing immunomodulatory properties of IVIG at high doses.
  • Combining lower-dose IVIG with antibody depletion via plasmapheresis.

Main Results:

  • Both IVIG monotherapy and plasmapheresis/IVIG combination successfully desensitize patients with donor-specific anti-HLA antibodies.

Related Experiment Videos

  • Excellent renal transplant outcomes have been achieved with these protocols.
  • The plasmapheresis/IVIG strategy is effective for ABO blood group incompatible renal transplantation.

    • Conclusions:

    • IVIG-based therapies represent effective strategies for incompatible renal transplantation.
    • These treatments address critical antibody-mediated barriers, improving transplant accessibility and outcomes.